Sign In
Buy CLPT
$13.30
+0.93 (+7.52%)
At Close: Jun 03, 2026
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025
05:02pm, Wednesday, 05'th Nov 2025
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / November 5, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigati
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 7, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigatio
The clearly established history across global regulatory bodies is expected to de-risk BioPharma partners' pathways towards achieving global scale and standardization. SOLANA BEACH, CALIFORNIA / ACCES
CLPT Expands Into Robotic System Supporting Cell and Gene Therapies
09:05am, Monday, 06'th Oct 2025
ClearPoint's new Robotic Neuro-Navigation System merges proven software with KUKA robotics to boost precision in cell and gene therapy delivery.
ClearPoint Neuro: AMT-130 Highlights A Bright Future
05:05pm, Thursday, 02'nd Oct 2025
ClearPoint's stock surged after uniQure announced strong Huntington's data, highlighting the value of its drug delivery platform. CLPT's technology has been validated by the AMT-130 data, positioning
ClearPoint Neuro Announces Development and Demonstration of the Company's Proprietary Robotic Neuro-Navigation System
04:05pm, Wednesday, 01'st Oct 2025
New Product Category Will Enable Added Flexibility to Support Commercial Launches of Cell and Gene Therapy SOLANA BEACH, CALIFORNIA / ACCESS Newswire / October 1, 2025 / ClearPoint Neuro, Inc. (Nasdaq
ClearPoint Neuro: Selling The Tools For Brain Therapies
05:50pm, Thursday, 25'th Sep 2025
ClearPoint Neuro surged over 100% following positive Huntington's Disease data from partner uniQure, highlighting its drug delivery device's role in AMT-130 trials. CLPT's SmartFlow cannula is already
ClearPoint Neuro Announces the Appointment of Dr. Paul Larson as Chief Medical Officer
04:05pm, Thursday, 25'th Sep 2025
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 25, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise naviga
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / September 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigat
ClearPoint Neuro: Biopharma Momentum Continues To Build
10:22pm, Thursday, 14'th Aug 2025
ClearPoint Neuro's Q2 results were solid; although real upside is likely to be more apparent from 2026 onward. Key catalysts include the launch of GLP services and partner program commercialization, p
ClearPoint Neuro, Inc. (CLPT) Q2 2025 Earnings Call Transcript
10:31pm, Tuesday, 12'th Aug 2025
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joseph Michael Burnett - President, CEO & Director Danilo D'Alessandro - Chief Fi
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates
07:06pm, Tuesday, 12'th Aug 2025
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.16 per share a year ago.
ClearPoint Neuro Reports Second Quarter 2025 Results
04:05pm, Tuesday, 12'th Aug 2025
Record Revenue and Substantial Cash Infusion Highlight the Company's ‘Fast. Forward.' Strategy SOLANA BEACH, CA / ACCESS Newswire / August 12, 2025 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Compa
ClearPoint Neuro Announces Progression of Key Partner Milestones throughout the Global Biologics and Drug Delivery Portfolio
04:05pm, Monday, 04'th Aug 2025
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / August 4, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to
ClearPoint Neuro to Announce Second Quarter 2025 Results August 12, 2025
04:05pm, Wednesday, 23'rd Jul 2025
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / July 23, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation
